POLARISE (the name refers to cell polarisation) is a single arm, multi-centre, phase II basket trial investigating the safety and activity of the use of ORBCEL-CTM in the treatment of patients with Primary Sclerosing Cholangitis (PSC), Rheumatoid Arthritis (RA), Lupus Nephritis (LN) and Crohn’s Disease (CD). Here, HSF4 is linked to rheumatoid arthritis.